• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Behavioral and Brain Science >Effect of Atomoxetine on Behavior of Outbred Mice in the Enrichment Discrimination Test
【24h】

Effect of Atomoxetine on Behavior of Outbred Mice in the Enrichment Discrimination Test

机译：富集鉴别试验中阿托西汀对离体小鼠行为的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Treatment of attention deficit hyperactivity disorder with medications is helpful in less than 60% of cases suggesting the necessity of development of novel drugs. The most accepted animal model of the disease is outbred spontaneously hypertensive rat strain. It was recently found in a novel enrichment discrimination test that the rat strain includes attentionally-low and -high phenotypes and clinically efficient drug for the treatment of the disorder atomoxetine is capable of ameliorating the enrichment discrimination by the attentionally-low rats. The present study aimed to test the generality of these findings in outbred CD-1 mice assessed in the same experimental design. The frequency distribution of the enrichment discrimination ratio differed from the curve expected under the normality hypothesis and had a bimodal shape suggesting the existence of attentionally-low and -high mouse phenotypes. Atomoxetine (3 mg/kg, orally, once daily for 4 days) selectively enhanced enrichment discrimination in mice of attentionally-low phenotype only. The present results generalize and extend findings previously reported in spontaneously hypertensive rats and suggest that the present model could be useful in studies of the neurobiological mechanisms of attention deficiency in rodents and for screening of novel drug candidates for treatment of attention deficit disorder.
机译：在不到60％的病例中，用药物治疗注意力不足过动症是有帮助的，这表明有必要开发新药。该疾病最公认的动物模型是自发性高血压大鼠品系。最近在新颖的富集鉴别测试中发现，大鼠品系包括注意低和高表型，并且用于治疗阿托西汀病症的临床有效药物能够改善注意低的大鼠的富集鉴别。本研究旨在测试在同一实验设计中评估的远交CD-1小鼠中这些发现的普遍性。富集判别率的频率分布与正常假设下预期的曲线不同，并且具有双峰形状，表明存在注意低和高小鼠表型。 Atomoxetine（3 mg / kg，口服，每天一次，连续4天）选择性地增强了仅具有注意力低表型的小鼠的富集歧视。本结果概括并扩展了先前在自发性高血压大鼠中报道的发现，并表明本模型可用于研究啮齿动物注意缺陷的神经生物学机制，并筛选用于治疗注意缺陷障碍的新型药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号